By Plenary Sessions: Aivar Sõerd

The speaker demonstrates profound knowledge in the fields of healthcare financing and pharmaceutical policy. He utilizes specific data, noting that only about one-fifth of the medicines authorized for sale in the European Union actually reach the Estonian market. The expertise focuses on the sluggishness of domestic procedures and the necessity of changing the operational model of the family doctor system.

The speaker demonstrates a high level of expertise in international corporate taxation and tax law, utilizing precise terminology such as "effective tax rate" and "multinational ultimate parent entity." They rely on facts and research, referencing a University of Tartu study and providing details regarding the adjustment of taxable profit based on labor costs and tangible fixed assets. Furthermore, the speaker is capable of naming the specific five Estonian groups currently affected by the directive.